EUVIMEDEUVIMED entdecken
Crossref

Ototoxicity in Pediatric Hematopoietic Stem Cell Transplantation With High‐Dose Carboplatin: Identifying Modifiable Risk Factors Through the Inclusion of Younger Patients

Anne Spence iD, Miranda Camet iD, Susan S Hayashi, Mary Claire McGlynn iD, Ningying Wu, Robert J Hayashi iD

Pediatric Blood & Cancer · 2025

DOI: 10.1002/pbc.31926 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2025. Verfasst von Anne Spence und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Division of Pediatric Hematology Oncology, Washington University in St. Louis, St. Louis, Missouri, USA. Hauptthemen laut MEDLINE: Carboplatin, Hematopoietic Stem Cell Transplantation, Ototoxicity, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Carboplatin ototoxicity is observed when used in high doses. We investigated risk factors associated with ototoxicity in high‐dose carboplatin hematopoietic stem cell transplantation (cHSCT) in a pediatric population.

Methods

We completed a retrospective analysis of medical and audiologic records for patients who underwent autologous cHSCT from January 1, 2008 to June 30, 2022. We accepted audiograms with a minimum requirement of threshold data at 4 kHz in at least one ear, allowing us to assess younger, more difficult to test patients and focus on hearing losses at important speech frequencies. Three audiologic outcome measures were evaluated—worsening in SIOP grade, significant change in hearing, and ototoxicity for audiograms with data up to 4 kHz and data up 8 kHz.

Results

Forty‐three cHSCTs from 29 patients had sufficient audiologic data. Ototoxicity was observed in 49% of the data up to 4 kHz and in 78% of the data up to 8 kHz. Cumulative dose of prior cisplatin (OR = 1.01, 95% CI = 1.002–1.014, p = 0.011) and cumulative dose of carboplatin in the preparative regimen (OR = 1.003, 95% CI = 1.001–1.004, p = 0.001), were associated with ototoxicity. Concurrent furosemide with carboplatin administration resulted in 100% ototoxicity, with patients demonstrating a mean change in SIOP grades by 2.0 SE ± 0.038.

Conclusion

Using criterion that allowed for the evaluation of very young children, this report demonstrates that cumulative dose of prior cisplatin, cumulative dose of carboplatin in the preparative regimen, and concomitant furosemide administration with carboplatin is associated with ototoxicity in cHSCT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CarboplatinHematopoietic Stem Cell TransplantationOtotoxicityAntineoplastic AgentsHearing LossHumansFemaleMaleChildRetrospective StudiesChild, PreschoolRisk FactorsAdolescentInfantFollow-Up StudiesPrognosis

Stichwörter der Autor:innen

carboplatinhematopoietic stem cell transplantationototoxicitypediatric

Substanzen

CarboplatinAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Pediatrics, Division of Pediatric Hematology Oncology, Washington University in St. Louis, St. Louis, Missouri, USA.
  • Biostatistics Shared Resource, Division of Public Health Sciences, Department of Surgery, The Alvin J. Siteman Comprehensive Cancer Center, School of Medicine, Washington University, St. Louis, Missouri, USA.

ORCID-Profile: Anne Spence, Miranda Camet, Mary Claire McGlynn, Robert J Hayashi

Förderung

  • NCI NIH HHS

Zitieren

APA

Spence, A., Camet, M., Hayashi, S. S., McGlynn, M. C., Wu, N., & Hayashi, R. J. (2025). Ototoxicity in Pediatric Hematopoietic Stem Cell Transplantation With High‐Dose Carboplatin: Identifying Modifiable Risk Factors Through the Inclusion of Younger Patients. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31926

Vancouver

Spence A, Camet M, Hayashi SS, McGlynn MC, Wu N, Hayashi RJ. Ototoxicity in Pediatric Hematopoietic Stem Cell Transplantation With High‐Dose Carboplatin: Identifying Modifiable Risk Factors Through the Inclusion of Younger Patients. Pediatric Blood & Cancer. 2025. doi:10.1002/pbc.31926

BibTeX
@article{Spence2025,
  author = {Spence, Anne and Camet, Miranda and Hayashi, Susan S and McGlynn, Mary Claire and Wu, Ningying and Hayashi, Robert J},
  title = {Ototoxicity in Pediatric Hematopoietic Stem Cell Transplantation With High‐Dose Carboplatin: Identifying Modifiable Risk Factors Through the Inclusion of Younger Patients},
  journal = {Pediatric Blood & Cancer},
  year = {2025},
  doi = {10.1002/pbc.31926}
}
Kostenlos starten →